GCM
VRTX icon

Gallacher Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Gallacher Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-827
Closed -$375K – 379
2025
Q4 		$375K Sell
827
-8
-1% -$3.45K 0.14% 193
2025
Q3 		$327K Buy
+835
New +$349K 0.13% 222
2024
Q2 		– Sell
-602
Closed -$252K – 320
2024
Q1 		$252K Sell
602
-15
-2% -$6.34K 0.13% 208
2023
Q4 		$251K Buy
617
+7
+1% +$2.59K 0.14% 203
2023
Q3 		$212K Buy
610
+24
+4% +$8.39K 0.13% 212
2023
Q2 		$206K Buy
+586
New +$197K 0.12% 227

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Gallacher Capital Management's VRTX Position: Q1 2026 in Review

Gallacher Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 827 shares — an estimated $375K sold.

Gallacher Capital Management first reported a position in VRTX in Q2 2023 and held it in 6 quarters. The position peaked at $375K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Gallacher Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Gallacher Capital Management sold 827 Vertex Pharmaceuticals shares in Q1 2026, an estimated $375K.
  • Gallacher Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2023 and held it in 6 quarters.
  • Gallacher Capital Management's Vertex Pharmaceuticals position peaked at $375K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Gallacher Capital Management's 13F filing for Q1 2026, filed 6 May 2026.